- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT04891640
Biologisk reduksjon og fangst av barns resultater og fakkelfrekvens ved spondyloartritt hos barn (BACK-OFF JSpA)
Biologisk reduksjon og fangst av barns resultater og fakkelfrekvens ved spondyloartritt hos barn (BACK-OFF JSpA)
This randomized pragmatic trial will generate knowledge about strategies used to de-escalate tumor necrosis factor inhibitor (TNFi) therapy in patients with juvenile spondyloarthritis with sustained inactive disease and are treated at one of the 31 participating pediatric healthcare systems. This open label study will be conducted in the setting of routine clinical care and will compare the risk and timing of flare (Aim 1) and patients' lived experiences (Aim 2) across three arms.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
This project is a prospective, 12-month (+/- 1 month) pragmatic randomized trial embedded within routine clinical care. Children with spondyloarthritis who have maintained inactive disease on a clinically prescribed standard dosing of a TNFi for 6 months or longer will be eligible for enrollment. Children will be randomized to one of the following alternative approaches: continued fixed standard dosing (arm 1), fixed longer dosing intervals of TNFi (arm 2), or stopping TNFi (arm 3). The recommended visit frequency is every 3 months (+/- 1 month) through the study endpoint at 12 months (+/- 1 month). After subjects have followed their treatment assignment for 12 months (+/- 1 month), those who have not flared may modify their treatment regimen as per shared decision making between themselves and the treating physician. All participants will be monitored for 24 additional months for long-term outcomes after the intervention period.
Studietype
Registrering (Faktiske)
Fase
- Fase 4
Kontakter og plasseringer
Studiesteder
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 1E8
- The Hospital for Sick Children
-
-
-
-
Alabama
-
Birmingham, Alabama, Forente stater, 35294
- University of Alabama at Birmingham
-
-
Arizona
-
Phoenix, Arizona, Forente stater, 85006
- Phoenix Children's
-
-
California
-
Los Angeles, California, Forente stater, 90027
- Children's Hospital Los Angeles
-
Palo Alto, California, Forente stater, 94304
- Stanford University
-
-
Colorado
-
Aurora, Colorado, Forente stater, 80045
- Children's Hospital of Colorado
-
-
Delaware
-
Wilmington, Delaware, Forente stater, 19803
- Nemours Children's Hospital
-
-
District of Columbia
-
Washington D.C., District of Columbia, Forente stater, 20010
- Children's National Health System
-
-
Florida
-
Orlando, Florida, Forente stater, 32827
- Nemours Children's Health
-
-
Georgia
-
Atlanta, Georgia, Forente stater, 30329
- Children's Healthcare of Atlanta
-
-
Illinois
-
Chicago, Illinois, Forente stater, 60611
- Ann & Robert H. Lurie Children's Hospital of Chicago
-
-
Indiana
-
Indianapolis, Indiana, Forente stater, 46202
- Riley Hospital for Children at IU Health
-
-
Iowa
-
Iowa City, Iowa, Forente stater, 52242
- University of Iowa Stead Family Children's Hospital
-
-
Massachusetts
-
Boston, Massachusetts, Forente stater, 02115
- Boston Children's Hospital
-
-
Michigan
-
Ann Arbor, Michigan, Forente stater, 48109
- University of Michigan
-
-
Minnesota
-
Minneapolis, Minnesota, Forente stater, 55455
- University of Minnesota Masonic Children's Hospital
-
-
Missouri
-
Kansas City, Missouri, Forente stater, 64108
- Children's Mercy Hospital
-
St Louis, Missouri, Forente stater, 63110
- St. Louis Children's Hospital
-
-
New York
-
New York, New York, Forente stater, 10021
- Hospital for Special Surgery
-
Queens, New York, Forente stater, 11040
- Cohen Children's Medical Center
-
-
Ohio
-
Akron, Ohio, Forente stater, 44302
- Akron Children's Hospital
-
Cincinnati, Ohio, Forente stater, 45229
- Cincinnati Children's Hospital Medical Center
-
Columbus, Ohio, Forente stater, 43205
- Nationwide Children's Hospital
-
-
Oregon
-
Portland, Oregon, Forente stater, 97227
- Randall Children's Hospital at Legacy Emanuel
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forente stater, 19104
- The Children's Hospital of Philadelphia
-
Pittsburgh, Pennsylvania, Forente stater, 15224
- UPMC Children's Hospital of Pittsburgh
-
-
Tennessee
-
Nashville, Tennessee, Forente stater, 37232
- Vanderbilt Children's Hospital
-
-
Texas
-
Dallas, Texas, Forente stater, 75390
- UT Southwestern Medical Center
-
Houston, Texas, Forente stater, 77030
- Texas Children's Hospital - Baylor College of Medicine
-
-
Utah
-
Salt Lake City, Utah, Forente stater, 84113
- Primary Children's Hospital
-
-
Washington
-
Seattle, Washington, Forente stater, 98105
- Seattle Children's Hospital
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
-
Males or females age 8 to 21 years
-
Juvenile SpA diagnosis:
• Symptom onset before their 16th birthday:
o International League of Associations for Rheumatology (ILAR) criteria for juvenile idiopathic arthritis enthesitis-related arthritis subtype
OR;
• Symptom onset before their 18th birthday:
o Pediatric Rheumatology International Trials Organization (PRINTO) revision of the ILAR criteria enthesitis spondylitis-related JIA
- Peripheral arthritis and enthesitis, or
- Arthritis or enthesitis, plus ≥3 months of inflammatory back pain and sacroiliitis on imaging, or
- Arthritis or enthesitis plus 2 of the following: (1) sacroiliac joint tenderness; (2) inflammatory back pain; (3) presence of HLA-B27 antigen; (4) acute (symptomatic) anterior uveitis; and (5) history of a SpA in a first-degree relative.
- If peripheral arthritis is present, it should persist for at least 6 weeks.
-
Currently taking one of the following TNFi therapies (Adalimumab, Certolizumab, Etanercept, Golimumab, Infliximab, or TNFi biosimilar) at standard doses
-
Have reached a clinically inactive disease state for a minimum of six months, as determined by treating physician
-
English speaking or Spanish speaking
-
Subject's treating physician recommended that he/she is a good candidate to participate in the study, which may include a modified therapy
-
Interested and willing to de-escalate TNFi therapy
Exclusion Criteria:
1) History of inflammatory bowel disease, history of uveitis that was not adequately controlled with localized ophthalmic treatment or psoriasis that pre-dates the start of TNFi therapy or psoriasis that started after TNFi therapy and has required more than topical therapy for control
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Aktiv komparator: TNFi Standard Therapy
Continue fixed standard treatment (i.e., no change from current therapy) |
Participants randomly assigned to this arm will continue taking their TNFi medication as currently prescribed. |
|
Eksperimentell: TNFi fixed longer dosing intervals
Fixed longer dosing intervals of TNFi (i.e., increased time between doses) |
Participants randomly assigned to this arm will increase the time between TNFi medication doses.
|
|
Eksperimentell: TNFi Therapy Withdrawal
Stop TNFi treatment |
Participants randomly assigned to this arm will stop TNFi medication. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Juvenile Spondyloarthritis (JSpA) flare
Tidsramme: 12 months
|
JSpA flare is defined as clinically meaningful worsening in ≥3 of the following: caregiver/patient assessment of well-being, physician assessment of disease activity, caregiver/patient assessment of pain, physical function, and active joint count. Meaningful change for well-being, disease activity, and pain are an increase of ≥2 on visual analogue scale (range 0-10 with higher scores indicating poorer well-being, higher disease activity, and higher magnitude of pain). Meaningful change in function is defined as ≥3 unit change in the PROMIS mobility or upper extremity T-scores. The Patient-Reported Outcomes Measurement Information System (PROMIS) short forms include 8 questions and a T-score of '50' represents the healthy population mean score with standard deviation of 10. Active joint count is defined as the number of joints with swelling or, in the absence of swelling, limitation of motion accompanied by pain or warmth as per the physician examination. |
12 months
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Pain interference (as measured by the PROMIS short form)
Tidsramme: 12 months
|
Pain interference (as measured by the PROMIS short form) of children with spondyloarthritis in the three treatment arms. The PROMIS short form is a validated questionnaire that measures the self-reported consequences of pain on relevant aspects of a person's life.The PROMIS short form includes 8 questions and a T-score of '50' represents the healthy population mean score with standard deviation equal to 10. |
12 months
|
Samarbeidspartnere og etterforskere
Samarbeidspartnere
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Andre studie-ID-numre
- 21-018442
- : GRT-00001036 (Annet stipend/finansieringsnummer: PCORI)
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .